TRIM21 and myositis disease: Based on these findings in our murine model of HRS-induced myositis, we examined serum anti-Ro52 and anti-Ro60 antibody titers in 177 anti-Jo-1 antibody-positive patients as well as several control groups that included healthy volunteers (n=30) and patients with non-Jo-1 anti-tRNA synthetase (n=20), anti-SRP (n=20), or anti–topoisomerase I (n=20) antibodies.